FDA
-
-
-
-
-
-
-
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
-
-
-
-
-
-
-
Pluri (PLUR) CEO Issues Update
-
-
-
-
-
-
-
Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
-
323,707 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

